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Background: The Lao Government changed the national policy for uncomplicated Plasmodium falciparum malaria
from chloroquine to artemether-lumefantrine (AL) in 2005. Since then, no information on AL efficacy has been
reported. With evidence of resistance to artemisinin derivatives in adjacent Cambodia, there has been a concern as
to AL efficacy. Monitoring of AL efficacy would help the Lao Government to make decisions on appropriate
malaria treatment.
Methods: The efficacy of a three-day, twice daily oral artemether-lumefantrine for the treatment of uncomplicated
falciparum malaria in Xepon District, Savannakhet Province, southern Laos was studied over 42 days follow-up. This
was part of a trial of thiamin supplementation in falciparum malaria.
Results: Of 630 patients with P. falciparum enrolled in the trial of thiamin treatment, 549 (87%, 357 children
≤15 years and 192 adults) were included in this study. The per protocol 42-day cure rates were 97% (524/541) [96%
(337/352) for children and 99% (187/189) for adults, p = 0.042]. By conventional intention-to-treat analysis, the 42-day
cure rates adjusted for re-infection, were 97% (532/549) [96% (342/357) in children and 99% (190/192) in adults,
p = 0.042]. The proportion of patients who remained parasitaemic at day 1 after treatment was significantly higher in
children [33% (116/356)] compared to adults [15% (28/192)] (p< 0.001) and only one adult patient had detectable
parasitaemia on day 2. There were no serious adverse events. Potential side effects after treatment were reported more
commonly in adults (32%) compared to children (15%) (p< 0.001). Patients with recrudescent infections were
significantly younger, had longer mean time to fever clearance, and had longer median time to parasite clearance
compared to those who were cured.
Conclusions: The current nationally-recommended anti-malarial treatment (artemether-lumefantrine) remains highly
efficacious for the treatment of uncomplicated falciparum malaria five years after introduction in Laos. Regular
monitoring is required in case artemisinin-resistant P. falciparum parasites should appear.
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Although the incidence of Plasmodium falciparum mal-
aria has declined recently in northern and central Lao
PDR (Laos), malaria remains an important cause of mor-
bidity and mortality in southern Laos, with an estimated
incidence of 4.7 to 23.5/1,000 population between 2006-
2008 [1-3]. The change of the Lao Government national
treatment policy for uncomplicated falciparum malaria
from chloroquine to artemether-lumefantrine in 2005
is likely to have contributed substantially to the reduc-
tion in the incidence of malaria in northern and central
Laos. This change was prompted by high levels of
P. falciparum resistance to chloroquine (CQ) and
sulphadoxine-pyrimethamine (SP) [4-8]. The use of artemi-
sinin combination therapy (ACT), artesunate +mefloquine,
artemether-lumefantrine (AL) and dihydroartemisinin-
piperaquine, has been shown to provide high cure rates
(42-day failure rate of≤6%) and good tolerability in Laos
[1,9-12].
However, artemisinin resistance has emerged in west-
ern Cambodia [13-15], raising serious concerns that re-
sistance could spread the ~ 400 km to southern Laos. In
2002-3, the 42-day cure rate following full treatment
with AL was 97% in southern Laos despite a low-fat diet
(which reduces lumefantrine absorption) and consequent
low day 7 plasma lumefantrine concentrations [9]. AL
has to be taken twice a day, and should be taken with
fats [16-20] which may compromise adherence and effi-
cacy respectively, so there is concern that AL efficacy
could decline, particularly if protection from the co-
administered artemether is compromised by emerging
resistance.
Artemisinin resistance is manifest by a slowing in
parasite clearance rates [15,21]. Reassuringly, of 861
patients with falciparum malaria recruited to three trials
in southern Laos treated with ACT between 2002 and
2008, only 2 (0.23%) patients had parasite clearance
times (PCT) longer than three days and 30 (3.48%) had
PCT longer than 2 days [22]. To determine whether
there has been any recent change, the efficacy of the na-
tionally recommended ACT (3-day oral artemether-
lumefantrine) for the treatment of uncomplicated falcip-
arum malaria was reported. This was part of a large trial
of thiamin treatment in P. falciparum malaria in south-
ern Laos, which will be reported separately.
Methods
Study site, patients, clinical and laboratory procedures
The study was conducted between June and November
from 2008-2010 at Xepon (30 beds) Inter-District Hos-
pital (16.690 N, 106.200 E, 208 metres above sea level),
Savannakhet Province, ~665 km southeast of Vientiane,
the capital of Laos. Xepon (88 villages, population
48,000) is inhabited predominantly by rice farmers ofthe Lao Theung ethnic groups. Malaria transmission is
seasonal with a peak during the rainy months of July
and August [22].
The clinical trial of thiamin supplementation in falcip-
arum malaria conducted among patients with P. falcip-
arum malaria receiving anti-malarial therapy according
to national guidelines, was an exploratory, double-blind,
parallel group, placebo-controlled, randomized (variable
blocks), superiority trial to compare the frequency of
clinical adverse effects and thiamin status, during 42 days
follow up, of either daily oral thiamin supplementation
([oral thiamin (5 mg tablet) (Olan-Kemed Co.Ltd, Bang-
kok, Thailand)] 10 mg immediately after anti-malarial
drugs, followed by 10 mg daily for 7 days followed by
5 mg daily until day 42), or an identical placebo.
Patients were included in the trial of thiamin treat-
ment provided that they or their guardians (in the case
of children) gave fully informed written consent, were of
any age, had microscopically confirmed P. falciparum in-
fection or mixed Plasmodium species infections, with a
history of fever, were willing and able to comply with the
study protocol for the duration of the 42 days follow up,
and had not taken a full course of any anti-malarial
drugs in the previous three days. Patients were excluded
if they had a history of hypersensitivity to thiamin or
artemether-lumefantrine, presented with intercurrent
non-malarial illness or any condition, which in the
judgement of the investigator would place the subject at
undue risk or interfere with the results of the study, and
if they had clinically apparent suspected thiamin defi-
ciency (beriberi) [23]. Patients included in the analysis
for this paper were only those without danger signs or
severe falciparum malaria [24], with P. falciparum
mono- or mixed infections with other species, but an
asexual P. falciparum parasite density of <250,000/μL,
and were able to swallow artemether-lumefantrine at
presentation.
Patients’ admission clinical details including current
and past medical history, pre-treatment, and findings
from physical examination were recorded on the case
record form. Venous blood samples were taken for para-
site counts, haematocrit, blood glucose, and lactate, and
three blood spots were collected on 3MM filter paper
(Whatman, Maidstone, UK) and stored in a plastic bag
with silica gel for later malaria genotype analysis [22,25].
For women of child bearing age a urinary pregnancy test
was performed before anti-malarial treatment was
prescribed.
If the study criteria were met, patients were admitted
to the hospital and treated with the nationally recom-
mended anti-malarial - artemether (20 mg)-lumefantrine
(120 mg) (Co-artemW, Novartis) provided by the Global
Fund to fight AIDS, Tuberculosis and Malaria: one dose
twice daily for three days. Dosing by body weight were
Mayxay et al. Malaria Journal 2012, 11:184 Page 3 of 10
http://www.malariajournal.com/content/11/1/184one tablet if <15 kg, two tablets if 15–24 kg, three
tablets if 25–34 kg, and four tablets if ≥35 kg. All
patients were asked to take fatty food with the anti-
malarial drugs and drug administration was directly
observed by a study nurse. For children who could not
swallow tablets, the appropriate drug dose was crushed
and mixed with water and given in a syringe. If vomiting
occurred within 30 minutes of anti-malarial administra-
tion, the full dose was repeated. Patient who vomited
within 30 minutes to one hour, a half dose was re-
administered. Patients who vomited >2 times within
one hour were given the rescue treatment (artesunate
2.4 mg/kg IV stat, followed by 2.4 mg/kg IV at 12 hours
and 24 hours and then daily until able to take oral
medication).
Vital signs (axillary temperature, pulse, respiratory
rate, and blood pressure) were measured every six hours.
Patients and parasite counts were reviewed daily until
two consecutive negative blood smears, then weekly for
42 days from the start of treatment or at other times if
they felt unwell. Patients were discharged only when
their fever and parasitaemia had cleared (defined as axil-
lary temperature <37.5°C and <1 parasite per 500 white
cells on thick film after 2 negative slides, respectively)
and were asked to return to the hospital at days 7, 14,
21, 28, 35 and 42 (or at any time the patients feel un-
well) or were visited at home in case the patients did not
return as planned.
At each weekly visit, the symptoms of the patients
during the previous week were recorded. Finger-prick
blood samples were taken for malaria blood smears and
haematocrit and blood spots were collected onto filter
paper strips from all patients with recurrent fever or
malaria symptoms. PCR amplification was performed on
paired samples for parasite genotyping to distinguish be-
tween reinfection and recrudescence using three parasite
loci (MSP-1, MSP-2, and GLURP) [25]. The PCR tests
were performed at the MORU malaria molecular labora-
tory, Bangkok, Thailand.
Patients with P. falciparum recurrence were retreated
with artesunate 4 mg/kg/day in a single daily dose for
3 days (Day 0-2) (Guilin Pharmaceutical Co., Guilin,
PRC) plus mefloquine 15 mg base/kg on day 1 and
10 mg base/kg on day 2 in single daily dose (LariamTM,
Roche Co, Switzerland). Those who had P. vivax appear-
ance during follow up were treated with chloroquine
(25 mg base/kg) for three days and further followed up.
The incidence of any adverse event was recorded. Writ-
ten informed consent was obtained from all participants.
Ethical clearance for the study was granted by the Lao
National Ethics Committee for Health Research and the
Oxford University Tropical Medicine Research Ethics
Committee (OXTREC). The trial is registered with the
ISRCTN via the University of Oxford as ISRCTN:85411059. The trial was monitored by the Clinical Trials
Support Group of Mahidol-Oxford Tropical Medicine
Research Unit, Bangkok, Thailand.
Outcome measures
The primary objective of the thiamin treatment trial was
to determine whether the frequency of adverse events,
after anti-malarial therapy, were significantly lower in
those who received thiamin supplementation in com-
parison to those who did not. Here the PCR-corrected
adequate clinical and parasitological responses at day 42
[26], the PCT (the time in hours from the first treatment
dose to the first of two consecutive thick films that were
negative for asexual falciparum parasites after checking
≥500 oil fields) and fever clearance times (FCT, time in
hours from the start of treatment at which the tympanic
temperature first dropped below 37.5°C and remained
below 37.5°C for 48 hours), gametocytaemia, the fre-
quency of adverse events, and changes in haematocrit
following anti-malarial treatment are described.
Statistical analysis
Data were analysed using Stata v9 (StataCorp, College
Station, TX, USA). Comparisons between two groups
were made by the Mann-Whitney U, Student’s t, chi-
square, and Fisher’s exact tests, as appropriate. Cure
rates were calculated as the proportion of patients with
PCR-confirmed recrudescence using intention-to-treat
(ITT) and per-protocol (PP) populations and by Kaplan-
Meier survival analysis. In the ITT population all losses
to follow-up were treated as failures and in the PP popu-
lation losses to follow-up were excluded from the ana-
lysis. Patients with new infections were regarded as
cures in both analyses. Gametocyte carriage was sum-
marized as person-gametocytes-week rates calculated as
the total number of weeks with gametocytes divided by
the total number of weeks of follow-up. To identify in-
dependent predictors of treatment response, a stepwise
logistic regression was constructed with recrudescence
as the dependent variable and sex, age, admission symp-
toms (headache, chill, myalgia, dizziness, vertigo, nausea,
vomiting, abdominal pain, diarrhea, anorexia, cough,
dyspnea, and weakness) and signs (drowsiness, spleno-
megaly, and hepatomegaly), gametocyte carriage at ad-
mission, admission temperature, baseline haematocrit,
fever and parasite clearance times, past history of malaria,
and P. vivax appearance during follow up included as cov-
ariates. Only factors that were significant at p< 0.05 were
retained in the final model.
Results
Of the 630 patients enrolled, 549 (87%; 276 randomized
to thiamin and 273 to identical placebo) were included
in the analysis for this paper. Patients were excluded
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parasitaemia >250,000/μL (n = 27) or were not able to
swallow tablets on admission (n = 20) (see above,
Figure 1). As the median (range) PCT (days) and mean
(95%CI) FCT (hours) did not differ significantly between
patients with and without thiamin supplementation [1
(1-3) vs 1 (1-3), p = 0.87; and 26.6 (24.7–28.6) vs 26.4
(24.4-28.4), p = 0.85, respectively] all 549 patients were
included in a single group. Admission and follow-up
haematocrit and gametocytaemia also did not signifi-
cantly differ between the two trial groups (p> 0.05).
Of the 549 patients (Figure 1), 538 (98%) had P. falcip-
arum mono-infection and 11 (2%) had mixed infections
(10 P. falciparum +P. vivax and 1 P. falciparum+ P.Lost to 
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(Table 1). One child with persistent vomiting after taking
AL was given parenteral artesunate and excluded from
the study. Four patients (two children and two adults)
were lost to follow up and three (two children and one
adult) withdrew their consent for further follow up.
Therefore, 352 (99%) and 189 (98%) children and adults,
respectively, completed 42 days follow up (Figure 1).
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Table 1 Admission demographic, clinical and laboratory details for patients included in the analysis of the efficacy of
artemether-lumefantrine (Coartem™) for the treatment of uncomplicated falciparum malaria in Laos
Variables Age groups
All (n = 549) Children (≤ 15 yrs) (n = 357) Adults (> 15 yrs) (n = 192)
Sex, M, no (%) 276 (50) 174 (49) 102 (53)
Age, years, median (range) 10 (0.5 - 73) 6 (0.5 - 15) 25 (16 – 73)
Body weight, kg 29.5 (28.0 – 30.9) 18.8 (17.8 – 19.8) 49.3 (48.2 – 50.4)
Height, cm 124.5 (122.0 –126.9) 108.4 (106.0 – 110.7) 154.4 (153.3 – 155.5)
Previous malaria attack, no. (%) of patientsa 151 (27.5) 89 (25) 62 (32)
Axillary temperature, °C 38.4 (38.3 - 38.5) 38.5 (38.4 - 38.7)* 38.2 (38.0 - 38.3)
Patients without fever on admission, no. (%) 147 (27) 87 (24) 60 (31)
Systolic blood pressure, mm Hg 101.9 (100.8 -103.1) 95.1 (94.2 - 96.1)* 114.6 (113.0 - 116.1)
Diastolic blood pressure, mm Hg 69.7 (68.8 – 70.6) 64.6 (63.7 - 65.5)* 79.3 (78.2 - 80.4)
Pulse, beats/min 95.1 (94.0 - 96.2) 100.4 (99.0 -101.8)* 85.3 (84.4 – 86.3)
Respiratory rate/min 27.5 (27.0 – 28.1) 29.7 (29.0 – 30.3)* 23.5 (22.9 – 24.0)
Splenomegaly, no. (%) of patients 140/547 (26) 123/355 (35)* 17/192 (9)
Hepatomegaly, no (%) of patients 116/547 (21) 112/355 (31.5)* 4/192 (2)
Lymphadenopathy, no (%) of patients 2/545 (0.4%) 2/356 (0.6%) 0
Parasitaemia, geometric mean parasites/μL (95%CI) 19,775 (17,244 – 22,678) 27,241* (23,281 – 31,875) 10,902 (8,567 – 13,872)
Mixed malaria species infection, no.(%) 11 (2) 8 (2) 3 (1.5)
Gametocytaemia, no. (%) of patients 23 (4) 19 (5) 4 (2)
Gametocytaemia, geometric mean parasite/μL (95%CI) 216 (110 – 423) 201 (97 – 415) 328 (13 – 8,195)
Haematocrit, % 35.8 (35.2 – 36.3) 33.7 (33.1 – 34.4)* 39.5 (38.7 – 40.4)
Glucose, mmol/L 6.09 (5.97 – 6.20) 6.09 (5.93 – 6.24) 6.08 (5.90 – 6.27)
Lactate, mmol/L 2.9 (2.8 – 3.0) 3.1 (2.9 – 3.2)* 2.8 (2.6 – 2.9)
NOTE. Data are presented as mean values (95% CI), unless otherwise indicated.
* Significantly different from the other group (p< 0.001).
a Defined as patient or patient’s guardian reporting that the patient had had a febrile illness with a positive malaria slide.
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geometric mean parasitaemia were significantly higher in
children compared to adults, as were the proportions of
patients with nausea, vomiting, irritability, or a palpable
spleen or liver at presentation. The frequencies of headache,
chill, myalgia, tinnitus, palpitations, and dyspnoea were sig-
nificantly lower in children compared with adults (Table 2).Fever and parasite clearance, and changes in haematocrit
At presentation, 73% of all patients were febrile, (body
temperature ≥37.5°C), while at day 2, 92% and 98% of
children and adults were afebrile (p = 0.004). The pro-
portion of patients who remained parasitaemic at day 1
after treatment was significantly higher in children (33%)
compared to adults (15%) (p< 0.001, Table 3) and only
one adult patient had parasites detected at day 2. The
mean FCT and median PCT were significantly longer in
children than in adults (Table 3). The mean haematocrit
at all time points (before and after treatment) was sig-
nificantly lower in children compared to adults. Baseline
(day 0) and day 28 mean haematocrits improvedsignificantly after treatment for both children and adults
(Paired t-test p< 0.001 for both groups, Table 3).
Plasmodium falciparum gametocyte carriage
Twenty-three (4%) patients presented with patent game-
tocytaemia on admission, 19 (5%) in children and 4 (2%)
in adults (p = 0.07). The admission geometric mean
gametocytaemia were similar for children and adults
(p = 0.60). The time to clearance of gametocytes was
longer in adults than in children but the difference was
not statistically significant (p = 0.07). After treatment
four children, but no adults, developed gametocytaemia
(all at day 1) without gametocytaemia on admission. The
median gametocyte-person-weeks was similar for chil-
dren and adults (Table 3).
Cure rates
Of 43 (7.8%) patients with subsequent P. falciparum re-
appearance (34 children, nine adults) PCR genotyping
indicated that among these recurrent infections 16/43
(37%) [14/34 (41%) and 2/9 (22%) children and adults,
Table 2 Admission symptoms and signs for patients included in the analysis of the efficacy of artemether-lumefantrine
(Coartem™) for the treatment of uncomplicated falciparum malaria in Laos
Symptoms and signs Total (n = 549) Age groups
Children (≤ 15 years) (n = 357) Adults (> 15 years) (n = 192) p-value
Headache* 372/404 (92) 189/212 (89) 183/192 (95) 0.02
Chill 498/549 (91) 316/357 (88.5) 182/192 (95) 0.01
Myalgia* 230/404 (57) 75/212 (35) 155/192 (81) <0.001
Weakness 523/549 (95) 337/357 (94) 186/192 (97) 0.19
Dizziness* 299/404 (74) 150/212 (71) 149/192 (78) 0.11
Vertigo* 112/404 (28) 59/212 (28) 53/192 (28) 0.96
Tinnitus * 83/404 (20.5) 24/212 (11) 59/192 (31) <0.001
Anorexia 490/549 (89) 323/357 (90) 167/192 (87) 0.20
Nausea* 268/405 (66) 158/213 (74) 110/192 (57) <0.001
Vomiting 296/549 (54) 211/357 (59) 85/192 (44) 0.001
Abdominal pain* 110/411 (27) 59/219 (27) 51/192 (26.5) 0.93
Diarrhoea 111/548 (20) 72/356 (20) 39/192 (20) 0.98
Insomnia* 313/549 (57) 203/357 (57) 110/192 (57) 0.92
Nightmare* 38/404 (9) 17/212 (8) 21/192 (11) 0.31
Palpitation* 173/404 (43) 62/212 (29) 111/192 (58) <0.001
Dyspnea* 141/546 (26) 76/354 (21) 65/192 (34) 0.002
Cough 125/549 (23) 76/357 (21) 49/192 (25.5) 0.25
Sore throat* 49/410 (12) 29/218 (13) 20/192 (10) 0.36
Irritable 10/547 (2) 10/355 (3) 0 0.01
Rash 1/549 (0.2) 1/357 (0.3) 0 1.00
Urticaria 4/549 (0.7) 2/357 (0.6) 2/192 (1) 0.61
Itch 4/549 (0.7) 2/357 (0.6) 2/192 (1) 0.61
Chest abnormality** 2/549 (0.4) 1/357 (0.3) 1/192 (0.5) 1.00
NOTE. Data are shown as number (%).
* Only children aged≥ 4 years were asked about these symptoms.
** Chest abnormality: crepitation, rhonchi.
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child with P. falciparum reappearance had undetermined
PCR result and, considering this child as having a recru-
descent infection, the overall 42-day cure rates per
protocol, excluding patients who were lost to follow up,
withdrew consent, had persistent vomiting, or re-infec-
tion, were 97% (524/541) [96% (337/352) and 99% (187/
189) for children and adults, respectively, p = 0.042].
When the patients with repeated vomiting, who were
lost to follow up or were withdrawn (censored at the
time last seen), considering the child with undetermined
PCR result as recrudescence, and regarding recrudescent
infections as failures, the 42-day cure rates (95%CI) by
survival analysis (Kaplan-Meier) were 99.0% (98.3 –
99.4%) for children and 99.8% (99.0 – 99.9%) for adults.
For the PCR adjusted survival analysis, the cure rates
(95%CI) were 99.0% (98.3 – 99.4%) and 99.8% (99.0 –
99.9%) for children and adults, respectively. Byconventional ITT analysis, the overall 42-day cure rates,
adjusted for re-infection, were 97% (532/549) [96% (342/
357) in children and 99% (190/192) in adults, p = 0.042].
Of 17 patients considered as having recrudescent infec-
tion (15 children and two adults), 15 (13 children and
two adults) had parasite recurrence at or before day 28.
Similarly, the 28-day cure rates by ITT analysis were
344/357 (96%) for children and 190/192 (99%) for adults.
The median (range) interval to recrudescent falciparum
infections was 21 (14–42) days. By ITT and per protocol
analyses, the 42-day PCR uncorrected cure rates for chil-
dren and adults were 323/357 (90%) vs 183/192 (95%);
(p = 0.04), and 323/352 (92%) vs 183/189 (97%)
(p = 0.02), respectively. Of 129 children aged <5 years,
six had recrudescent infection and one had undeter-
mined PCR result. If the patient with undetermined PCR
result was considered a recrudescent infection, the 42-
day PCR corrected cure rates among children< 5 years
Table 3 Outcome measures for the treatment of patients included in the analysis of the efficacy of artemether-
lumefantrine (Coartem™) in the treatment of uncomplicated falciparum malaria in Laos
Variables Age groups
All (n = 549) Children (age≤ 15 yrs) (n = 357) Adults (age> 15 yrs) (n = 192)
42-day cure rate, no. (%) of patients a 532/549 (97) 342/357 (96)* 190/192 (99)
42-day cure rate per protocol, no. (%) of patientsΨ 524/541 (97) 337/352 (96)* 187/189 (99)
Fever clearance time, mean hours (95%CI)a,b 25.3 (23.9-26.8) 27.6 (25.7 – 29.5)* 21.2 (19.2 – 23.2)
Patients remained febrile at day 1, no. (%) 241 (44) 169 (47)* 72 (37.5)
Patients remained febrile at day 2, no. (%) 33 (6) 29 (8)* 4 (2)
Parasite clearance time, median days (range)a,c 1 (1 - 3) 1 (1 - 2)* 1 (1 - 3)
Positive parasitaemia at day 1, no. (%) of patients 144/548 (26) 116/356 (33)* 28/192 (15)
Positive parasitaemia at day 2, no. (%) of patients 1 0 1
Gametocytaemia detected at anytime, no.(%) of patients 27 (5) 23 (6) 4 (2)
Gametocytaemia after treatment, no. (%) of patients 4 (0.73) 4 (1.12) 0
Gametocyte clearance time, median days (range) d 7 (1 – 21) 3 (1 -21) 7 (7 – 14)
Gametocyte cleared by day 7, no. (%) d 24 (89) 21 (91) 3 (75)
Median (range) gametocyte-person-weeks d 0.42 (0.14 – 1.0) 0.42 (0.14 – 1.0) 0.42 (0.42 – 0.42)
P. vivax appearance after treatment for
P. falciparum, no. (%) of patients
18/594 (3) 17/357 (5)* 1/192 (0.5)
Day 0 haematocrit, mean % (95%CI) 35.8(35.2 – 36.3) 33.7 (33.1 – 34.4)* 39.5 (38.7 – 40.4)
Day 1 haematocrit, mean % (95%CI) 32.4 (31.9 – 32.9) 30.4 (29.8 – 30.9)* 36.2 (35.4 – 36.9)
Day 2 haematocrit, mean % (95%CI) 31.1 (30.6 – 31.6) 29.1 (28.5 – 29.6)* 34.9 (34.1 – 35.7)
Day 3 haematocrit, mean % (95%CI) 31.1 (30.6 – 31.6) 29.0 (28.5 – 29.6)* 34.9 (34.1 – 35.6)
Day 7 haematocrit, mean % (95%CI) 33.3 (32.9 – 33.7) 31.7 (31.2 – 32.1)* 36.3 (35.6 – 37.0)
Day 14 haematocrit, mean % (95%CI) 34.4 (34.0 – 34.8) 33.3 (32.9 – 33.7)* 36.5 (35.8 – 37.2)
Day 21 haematocrit, mean % (95%CI) 35.6 (35.2 – 35.9) 34.6 (34.2 – 35.0)* 37.5 (36.8 – 38.2)
Day 28 haematocrit, mean % (95%CI) 36.2 (35.8 – 36.5) 35.3 (34.9 – 35.7)* 37.8 (37.0 – 38.5)
Day 35 haematocrit, mean % (95%CI) 36.5 (36.1 – 36.8) 35.5 (35.2 – 35.9)* 38.2 (37.5 – 38.9)
Day 42 haematocrit, mean % (95%CI) 37.6 (37.2 – 37.9) 36.7 (36.3 – 37.0)* 39.4 (38.7 – 40.1)
NOTE. Ψ The patient with undetermined PCR result was classified as recrudescent infection.
a Intention-to-treat analysis.
b Data were available from 340 and 184 patients in children and adults groups, respectively.
c Data were available from 356 and 192 patients in children and adults groups, respectively.
d Data were available from 23 and 4 patients in children and adults groups, respectively.
* Significant difference from the other group (p< 0.05).
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ing the follow-up period, of which 17 were in children (p
< 0.05). The median (range) interval to P. vivax appear-
ance was 28 (21–42) days (Table 3).
Factors affecting treatment response
Patients with recrudescent infections were significantly
younger [median (range) age 5 (2–25) years], than those
whose infections were treated successfully [median
(range) age 10 (0.5–73) years, p = 0.006]. Considering the
child with undetermined PCR result as recrudescent in-
fection, the proportion of treatment failures adjusted for
re-infection by PCR among children was 4.2% (15/357
patients) compared with 1.0% (2/192 patients) among
adults (p = 0.042). The admission mean (95%CI) bodytemperature was significantly higher in patients with re-
crudescent infections [39.1 (38.4–39.8)°C] than those
who were cured [38.4 (38.3–38.5) 0 C, p = 0.01]. Patients
with recrudescent infections had a significantly longer
mean FCT (45.0 h; 95% CI, 32.3–57.8 h) than those
patients without (24.8 h; 95%CI, 23.4–26.2 h; p< 0.001).
Patients with recrudescent infections also had a signifi-
cantly lower haematocrit at days 3, 14, 21, 28, and 35
after starting therapy than those without recrudes-
cence detected (p = 0.03, p = 0.01, p< 0.001, p< 0.001,
and p< 0.001, respectively). The proportion of the
patients reporting a past history of malaria was signifi-
cantly lower in the patients with recrudescent infection
(6%) compared to those without (28%) (p= 0.043). In a
multiple logistic regression analysis, admission high
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longer fever clearance times [OR=1.0, 95%CI= 1.0 – 1.1,
p = 0.01], and lower haematocrit at day 28 [OR=0.7, 95%
CI= 0.6 – 0.9, p = 0.005] were significantly associated with
treatment failure.
Adverse events
The possible adverse events following treatment with AL
are shown in Table 4. Adverse event symptoms were
recorded for only those 467 (85%) patients aged ≥4 years
old and able to answer questions. No serious adverse
events including deaths were found during follow up.
The proportion of patients with at least one recorded
potential side effect after treatment was significantly
higher in adults (32%) compared to children (15%)
(p< 0.001), but this could be due to difficulties of obtain-
ing histories from children. The incidence of post-
treatment insomnia, weakness, anorexia, diarrhoea, night-
mares and palpitation were all significantly higher in
adults compared to children (p< 0.05) (Table 4).
Discussion
This large clinical trial shows that artemether-
lumefantrine retains excellent efficacy in the treatmentTable 4 Possible adverse events (AE) found in patients includ
lumefantrine (Coartem™) in the treatment of uncomplicated f
Variables
All (N = 549) Children (age≤ 15 y
At least one adverse event 114/549 (21%) 52/357 (15%)
Headache 32/403 (8%) 13/211 (6%)
Insomnia 31/549 (6%) 14/357 (4%)
Weakness 29/549 (5%) 12/357 (3%)
Anorexia 30/549 (5%) 14/357 (4%)
Diarrhoea 25/549 (5%) 11/357 (3%)
Nightmare 17/403 (4%) 4/211 (2%)
Abdominal pain 12/410 (3%) 5/218 (3%)
Dizziness 11/403 (3%) 4/211 (2%)
Vomiting 10/549 (2%) 8/357 (2%)
Nausea 5/403 (1%) 2/211 (1%)
Palpitation 5/404 (1%) 0
Itch 5/549 (1%) 3/357 (1%)
Vertigo 1/403 (0.25%) 0
Tinnitus 1/404 (0.25%) 0
Rash 1/549 (0.2%) 1/357 (0.3%)
Urticaria 1/549 (0.2%) 0
Irritability 0 0
Dyspnoea 0 0
Hearing loss 0 0
* Symptoms are given for only those 467 patients aged≥ 4 years old and able to an
asked about their charges insomnia, weakness, anorexia and itch.of uncomplicated falciparum malaria at one site in
southern Laos in both children and adults with 42-days
PCR-corrected cure rates of 96% and 99%, respectively.
These results are similar to those described in a com-
parable trial conducted in 2002-3 in nearby Phalanxay
District (~60 Km west of Xepon), in which there was a
42-days cure rate of 97% in children and adults [9]. A
similar trial conducted in the northern Luang Namtha
Province of Laos in 2003 also showed very good effi-
cacy and tolerability of AL with a 42-days cure rate of
94% [11]. As previously, AL was very well tolerated,
proved safe and no serious adverse events were found
during follow up.
Patients’ background immunity contributes substantially
to the treatment response of uncomplicated malaria in Laos
[6,27]. In this study, children had significantly higher recru-
descence rates and P. vivax appearance rates than adults. A
study comparing oral chloroquine and sulphadoxine-
pyrimethamine for the treatment of uncomplicated falcip-
arum malaria, before the introduction of AL, found treat-
ment failure rates among Lao children to be 4.9 times
higher than those among adults [6]. The contribution of
immunity to the treatment response is also suggested by
slower clearance of fever and parasitaemia among childrened in the analysis of the efficacy of artemether-
alciparum malaria in Laos*
Age groups





















swer questions about these symptoms, except that parents/guardians were
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conducted only in adults, may overestimate anti-malarial
efficacy risking continuation of ineffective drug regimens
in national policy [28]. Anti-malarial pharmacokinetics
may differ in children and but for artemether-lumefantrine
these differences are small [29].
The evidence, both from a trial of artesunate mono-
therapy with a mean (95%CI) PCT (hours) of 23.2
(21.2-25.3) and 42-day PCR-corrected cure rate of
100% [22], and from the high efficacy of AL described
here, at the same site, suggests that artemisinin resist-
ant P. falciparum has not spread to this area, of
southern Laos. However, regular monitoring of the
clinical efficacy of artemisinin-derivatives in southern
Laos, especially closer to the Cambodian border, is
required.
Conclusion
The Lao nationally recommended anti-malarial drug
(artemether-lumefantrine) remains highly efficacious for
the treatment of uncomplicated falciparum malaria five
years after its introduction. However, regular monitoring
of the efficacy of artemisinin derivatives is essential as
early warning of the potential spread of artemisinin-
resistant P. falciparum parasites.
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